The nation of Zimbabwe has rejected a significant American health deal worth 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on sensitive biological samples.
This move came to light after a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa felt the deal was "skewed".
An official representative has since clarified that the US was seeking biological samples for research and commercial gain while refused to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further dialogue to reach a agreement suitable to both sides so the country's vital HIV programme can continue.
Broader Implications
This rejection comes after a similar case in neighbouring Kenya, where a high court suspended a similar health funding agreement after concerns were filed about the security of Kenyans' medical information.
After resuming office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to boost transparency and accountability.
According to reports, 16 nations in Africa have to date agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to provide its genetic material and health information indefinitely, without any equivalent assurance of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the basic resources for medical research without any certainty that the end products would be available to our population if a new health crisis arise."
Sovereignty and International Frameworks
He also noted that the American exit from the global health body and its push of one-on-one deals were disrupting structures already set up via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to deal with potential pandemics.
"This system is intended to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
These objections over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to further discussions with our US partners on how subsequent collaboration could be arranged in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it recognised the government's concerns, but urged that negotiations must proceed considering much of the country's HIV programmes depended on foreign aid.
"In cases where specific concerns arise, such as those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it said.
This impasse highlights the complex tensions between accepting vital foreign assistance and safeguarding national sovereignty in an increasingly interconnected world.